## **COPY SUBMITTED IN IDS**

## INTERNATIONAL SEARCH REPORT

Form PCT/ISA/210 (second sheet) (July 1998)

International application No. PCT/JP03/13063

A. CLASS	SIFICATION OF SUBJECT MATTER	W30/305 %61D35/00 %611	p37/02		
Int.Cl7 C07K16/18, C12P21/08, A61K39/395, A61P35/00, A61P37/02, A61P43/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum d	ocumentation searched (classification system followed	by classification symbols)			
int.	C1 <sup>7</sup> C07K16/18, C12P21/08, A61P43/00	K39/395, A61P35/00, A61	P37/02,		
Documental	tion searched other than minimum documentation to th	e extent that such documents are included	in the fields searched		
Electronic d	ata base consulted during the international search (nan	ne of data base and, where practicable, sea	rch terms used)		
WPI(	DIALOG), BIOSIS(DIALOG), JSTP1 Bank/EMBL/DDBJ/GeneSeq, SwissE	lusu (JOIS) ,			
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where a		Relevant to claim No.		
X A	GENESTIER L. et al., Fas-ind activated T cells induced by class I αl domain., Blood 19	antibodies to the HLA	1-3 4-23		
x	pages 3629 to 3639 MATSUOKA S. et al., A novel	type of cell death of	1-3		
Ā	lymphocytes induced by monociparticipation of complement. Vol.181, No.6, pages 2007 to	lonal antibody without , J.Exp.Med.1995,	4-23		
X A	FAYEN J. et al., Negative sig class I antibodies is depende events., Int.Immunol.1998, Vo pages 1347 to 1358	ent upon two triggering	1-3 4-23		
× Furthe	er documents are listed in the continuation of Box C.	See patent family annex.			
* Special categories of cited documents:  "T" later document published after the international filing date or "A" document defining the general state of the art which is not priority date and not in conflict with the application but cited					
considered to be of particular relevance		priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
date "L" document which may throw doubts on priority claim(s) or which is		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered involve an inventive step when the document is taken alone			
cited to establish the publication date of another citation or other special reason (as specified)  "Y" document of particular relevance; the claimed invention cannot considered to involve an inventive step when the document is			when the document is		
"U" document reterring to an oral disclosure, use, exhibition or other combined with one or more other such documents, such means			documents, such		
"P" document published prior to the international filing date but later "&" document member of the same patent family than the priority date claimed					
Date of the actual completion of the international search 05 November, 2003 (05.11.03)		Date of mailing of the international search report 18 November, 2003 (18.11.03)			
Name and mailing address of the ISA/ Japanese Patent Office		Anthorized officer			
Facsimile No.		Telephone No.			

## **COPY SUBMITTED IN IDS**

## INTERNATIONAL SEARCH REPORT

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

International application No. PCT/JP03/13063

	tion). DOCUMENTS CONSIDERED TO BE RELEVAN'I	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y A	ONO K. et al., The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity., Mol.Immunol. 1999, Vol.36, No.6, pages 387 to 395	1-4 5-23
Y A	OHTOMO T. et al., Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells., Biochem. Biophys.Res.Commun.1999, Vol.258, No.3, pages 583 to 591	1-4 5-23
YA	OZAKI S. et al., Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells., Blood 1999, Vol.93, No.11, pages 3922 to 3930	1-4 5-23
		·